A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.
Overview
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) is a phase 3 interventional study registered as NCT06051409 by Ascentage Pharma Group Inc., with 350 participants planned, started 2023-08-31. Conditions listed: Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive. No results are recorded here; the registry entry is the source.
Setting
A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Investigator's Choice of TKI Combined With Chemotherapy in Patients With Newly Diagnosed Ph+ ALL
Phase
Phase 3
Sponsor
Ascentage Pharma Group Inc.
Registry
Enrolled
350
Similar pages
not linked directly; found by shared links- TrialStudy of Olverembatinib (HQP1351) in Patients With CML-CP
Shares Olverembatinib, Ascentage Pharma.
- TrialA Study of Olverembatinib in SDH-deficient GIST.
Shares Olverembatinib, Ascentage Pharma.
- TrialStudy of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Shares Olverembatinib, Ascentage Pharma.
- TargetBCR::ABL1 (Philadelphia chromosome)
Shares Olverembatinib, Ascentage Pharma.
- CancerChronic myeloid leukaemia (CML)
Shares Olverembatinib, Ascentage Pharma.